医学
维多利祖马布
结肠炎
血性腹泻
内科学
胃肠病学
英夫利昔单抗
腹泻
免疫疗法
易普利姆玛
炎症性肠病
癌症
疾病
作者
Zhe Zhang,Chang-Qing Zheng
出处
期刊:World Journal of Clinical Cases
[Baishideng Publishing Group Co (World Journal of Clinical Cases)]
日期:2022-10-16
卷期号:10 (29): 10550-10558
被引量:1
标识
DOI:10.12998/wjcc.v10.i29.10550
摘要
Immune check-point inhibitors-induced colitis (ICPIs-induced colitis) is one of the immune-related side effects. Steroids and Infliximab are commonly used to treat it. The patients of our report were treated by Vedolizumab.The two patients went to the doctor with bloody stools and were treated by Sintilimab and Camrelizumab, respectively, for their malignant tumors. They were diagnosed as ICPIs-induced colitis based on endoscopic and histologic examination. The original immunotherapy was ceased while the anti-inflammatory therapy was introduced. The patients' colitis symptoms disappeared after the treatment and no recurrence was found during the follow-up period. The unique feature about the case reports is that Vedolizumab combined with short-term corticosteroids had achieved good therapeutic effects.For the symptoms of bloody diarrhea after the ICPIs treatment of cancer, the possibility of ICPIs-induced colitis should be considered. Vedolizumab combined with short-term corticosteroids may be appropriate for the treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI